7-chloro-4-hydroxy-2-(4,5,6,7-tetrahydrobenzo[b]thiophen-4-yl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione | 406938-67-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-chloro-4-hydroxy-2-(4,5,6,7-tetrahydrobenzo[b]thiophen-4-yl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione
• 英文别名: 7-Chloro-2-(4,5,6,7-tetrahydro-1-benzothiophen-4-yl)-3,5-dihydropyridazino[4,5-b]quinoline-1,4,10-trione
• CAS: 406938-67-8
• 化学式: C₁₉H₁₄ClN₃O₃S
• 分子量: 399.857
• InChiKey: FIMGMTJHUKIZAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  27
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• 1, 2, 5, 10-tetrahydropyridazino[4, 5-b]quinoline-1,10-diones and their use for the treatment of pain
  申请人：——

  公开号：US20040058927A1

  公开（公告）日：2004-03-25

  Compounds useful for the treatment of pain in accord with structural diagram (I), or tautomers or pharmaceutically-acceptable salts of such compounds, wherein R 1 and A are as disclosed in the specification. Also disclosed are methods for the treatment of pain using compounds according to structural diagram (I) and pharmaceutical compositions comprising compounds according to structural diagram (I).

  本发明涉及与结构图(I)相符的用于治疗疼痛的化合物，或其互变异构体或药物可接受的盐，其中R1和A如本说明书所述。本发明还揭示了使用结构图(I)中的化合物治疗疼痛的方法以及包含结构图(I)中的化合物的制药组合物。
• 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-B]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN
  申请人：AstraZeneca AB

  公开号：EP1325002A1

  公开（公告）日：2003-07-09
• 1,2,5,10-TETRAHYDROPYRIDAZINO¬4,5-B|QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN
  申请人：AstraZeneca AB

  公开号：EP1325002B1

  公开（公告）日：2006-05-24
• US6833368B2
  申请人：——

  公开号：US6833368B2

  公开（公告）日：2004-12-21
• [EN] 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN<br/>[FR] 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES ET LEUR UTILISATION POUR TRAITER LA DOULEUR
  申请人：ASTRAZENECA AB

  公开号：WO2002026738A1

  公开（公告）日：2002-04-04

  Compounds useful for the treatment of pain in accord with structural diagram (I), or tautomers or pharmaceutically-acceptable salts of such compounds, wherein R1 and A are as disclosed in the specification. Also disclosed are methods for the treatment of pain using compounds according to structural diagram (I) and pharmaceutical compositions comprising compounds according to structural diagram (I).